| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 12/03/2009 | US20090298849 Materials and Methods Relating to the Induction of Apoptosis in Target Cells |
| 12/03/2009 | US20090298791 Combinations comprising epothilones and antimetabolites |
| 12/03/2009 | US20090298789 arresting heart of subject in need of heart surgery by exposing heart to effective amounts of a compound chosen from a potassium channel opener, a potassium channel agonist, an adenosine receptor agonist, and a local anaesthetic under conditions sufficient for heart to be arrested |
| 12/03/2009 | US20090298752 Aplidine treatment of cancers |
| 12/03/2009 | US20090297594 Oral Pharmaceutical Dosage Forms Comprising a Proton Pump Inhibitor and a NSAID |
| 12/03/2009 | US20090297579 Control of Cells and Cell Multipotentiality in Three Dimensional Matrices |
| 12/03/2009 | US20090297551 Adjuvant |
| 12/03/2009 | US20090297540 Induction of Indoleamine 2,3-Dioxygenase in Dendritic Cells by TLR Ligands and Uses thereof |
| 12/03/2009 | US20090297517 Methods for treating il-18 mediated disorders |
| 12/03/2009 | US20090297488 Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
| 12/03/2009 | US20090297487 Method for introducing sirna into cells by photochemical internalisation |
| 12/03/2009 | CA2726198A1 Inhibitor of analgesic tolerance |
| 12/03/2009 | CA2725445A1 Antifungal combination therapy |
| 12/02/2009 | EP2128272A1 Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor |
| 12/02/2009 | EP2127681A1 Therapeutic agent for periodontal disease and alveolar bone loss due to surgery |
| 12/02/2009 | EP2127676A2 Treatment of obesity and related disorders |
| 12/02/2009 | EP2127675A1 Antiviral agent |
| 12/02/2009 | EP2127673A1 Pharmaceutical agent for prevention and treatment of skin disease induced by accelerated keratinization |
| 12/02/2009 | EP2127672A1 Inhibitor of herpesvirus infection, method for inhibition of herpesvirus infection, and use thereof |
| 12/02/2009 | EP2127658A1 Therapeutic agent for meniere s disease |
| 12/02/2009 | EP2127652A1 Method for treating cancer using anticancer agent in combination |
| 12/02/2009 | EP2127650A2 Carbapenem antibacterials with gram-negative activity and processes for their preparation |
| 12/02/2009 | EP2126051A1 A method for expanding monocytes |
| 12/02/2009 | EP2125021A1 Combination therapy of lower urinary tract disorders with 2 ligands and nsaids |
| 12/02/2009 | EP2124884A2 Compositions comprising bile acid sequestrants for treating esophageal disorders |
| 12/02/2009 | EP1696737B1 Edible compositions which are adapted for use by a companion animal |
| 12/02/2009 | EP1503763B1 Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith |
| 12/02/2009 | EP1463440B1 Prevention of flap necrosis in plastic surgery |
| 12/02/2009 | EP1414459B1 Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| 12/02/2009 | EP1392683B1 Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and their use as anticancer agents |
| 12/02/2009 | EP1370270B1 Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs |
| 12/02/2009 | EP1349841B1 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 12/02/2009 | EP1313820B1 Adhesive blends comprising hydrophilic and hydrophobic pressure sensitive adhesives |
| 12/02/2009 | CN101594884A Protective agent for retinal nerve or optic nerve |
| 12/02/2009 | CN101590242A Method for preparing chitosan or sodium alginate-modified carbon nanotube-targeted slow release carrier |
| 12/02/2009 | CN101590240A Composition containing angiotensin II receptor antagonist, statin and folic acid as well as applications thereof |
| 12/02/2009 | CN101590239A Pharmaceutical composition containing uretic, statin and folic acid as well as applications thereof |
| 12/02/2009 | CN101590238A Composition containing angiotensin converting enzyme inhibitor, statin and folic acid as well as applications thereof |
| 12/02/2009 | CN101590237A Composition containing calcium channel blocker and folic acid as well as application thereof |
| 12/02/2009 | CN101590236A Composition containing calcium antagonist and Statins and application thereof |
| 12/02/2009 | CN101590235A Composition containing calcium channel blocker and B vitamins as well as application thereof |
| 12/02/2009 | CN101590234A Composition containing statins and B vitamins as well as application thereof |
| 12/02/2009 | CN101590233A Composition containing calcium channel blocker, statins and B vitamins as well as application thereof |
| 12/02/2009 | CN101590232A Pharmaceutical composition containing angiotensin converting enzyme inhibitors, lipid-lowering statins and nicotinic acid and application thereof |
| 12/02/2009 | CN101590231A Pharmaceutical composition containing angiotensin II receptor blockers, lipid-lowering statins and nicotinic acid and application thereof |
| 12/02/2009 | CN101590230A Pharmaceutical composition containing renin inhibitor, diuretic agent and folic acid and application thereof |
| 12/02/2009 | CN101590229A Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
| 12/02/2009 | CN101590228A Application of carbon monoxide release molecules in preparing medicament for treating early sepsis |
| 12/02/2009 | CN101590084A Pharmaceutical composition containing angiotensin converting enzyme inhibitors, B vitamins and ginkgo biloba extracts |
| 12/02/2009 | CN101590062A Use of pregnane-diones or diols as neuropathic analgesic agents |
| 12/02/2009 | CN101590057A Antitumor compositions containing taxane derivatives |
| 12/02/2009 | CN101590053A Drug combination containing nicotinic acid, statins compound and TZD compound |
| 12/02/2009 | CN101590052A Pharmaceutical composition containing calcium channel blockers, lipid-lowering statins and nicotinic acid and application thereof |
| 12/02/2009 | CN101590051A Drug combination containing nicotinic acid, HMG-CoA reductase inhibitor and alpha-glucosidase inhibitor |
| 12/02/2009 | CN101590040A Composition containing indapamide and B vitamins as well as application thereof |
| 12/02/2009 | CN101590039A Composition containing indapamide and statins as well as application thereof |
| 12/02/2009 | CN100564377C Substituted 4H-chromenes and analogs as activators of caspase and inducers of apoptosis and use thereof |
| 12/02/2009 | CN100563711C Slow-released anticancer injection |
| 12/02/2009 | CN100563710C Slow-released anticancer medicine preparation containing pyrimidine analog |
| 12/02/2009 | CN100563707C Activation and inhibition of the immune system |
| 12/02/2009 | CN100563656C Tamper-resistant oral opioid agonist |
| 12/01/2009 | US7626032 4-Amino-3,3-dimethylpiperidine; reduced toxicity, and improved pharmacology and pharmacokinetics |
| 12/01/2009 | US7625999 Immobilization on solid support |
| 12/01/2009 | US7625916 Medicinal composition |
| 12/01/2009 | US7625913 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 12/01/2009 | US7625887 e.g. 2-[3,5-trans-5-(3-aminophenyl)-7-chloro-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-N-(2-fluorobenzyl)acetamide; G-protein-coupled receptor (TGR5) agonist; central nervous system diseases; antiinflammatory agent; learning enhancement; angina pectoris, arrhythmia, bronchial asthma |
| 12/01/2009 | US7625879 Phosphohalohydrins, process for the production thereof and use thereof |
| 12/01/2009 | US7625875 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| 12/01/2009 | US7625860 Administering a combination of a cytotoxic agent and a fibroblastic growth factor antagonist, wherein the FGF antagonist enhances the efficacy of the cytotoxic agent |
| 12/01/2009 | US7625751 WNV core protein/capsid interacting protein and uses of the same |
| 12/01/2009 | US7625713 Process for identifying a ligand that binds to the NEP binding site for the SMR1 pentapeptide |
| 12/01/2009 | US7625711 Screening method for the identification of a drug for the development of an agent for prevention and/or treatment of Alzheimer's disease |
| 12/01/2009 | US7625583 Microbiocidal fatty acids such as palmitoleic acid and lauric acid |
| 12/01/2009 | US7625582 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| 12/01/2009 | US7625573 Immunology active materials; anticancer agents, infections, autoimmune diseases, parasiticides; lipid bilayer with antitumor agent |
| 12/01/2009 | US7625569 Vaccines; fusion protein; induce immunology response |
| 12/01/2009 | US7625558 Anticancer agents; administering nucleic acid which dimerizes with protein |
| 12/01/2009 | CA2572461C Physiological compatible film |
| 12/01/2009 | CA2418348C Oil/fat composition |
| 12/01/2009 | CA2407210C Liposome drug delivery |
| 12/01/2009 | CA2401878C Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation |
| 12/01/2009 | CA2265547C Method of treating endothelial injury |
| 12/01/2009 | CA2208503C Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders |
| 11/26/2009 | WO2009143403A1 Combination therapy for the management hypertension |
| 11/26/2009 | WO2009143078A2 Methods of treating brain cancer using hexose compounds |
| 11/26/2009 | WO2009142755A2 Methods of nourishing animals |
| 11/26/2009 | WO2009142271A1 Cancer stem cell having high level of sld5 expression therein |
| 11/26/2009 | WO2009142242A1 Composition for preventing cardiovascular event in high-risk patient |
| 11/26/2009 | WO2009142195A1 Agent for induction/maintenance of remission |
| 11/26/2009 | WO2009141738A2 Modified drugs for use in liposomal nanoparticles |
| 11/26/2009 | WO2009141406A1 Maintenance therapy regimen for treating acne |
| 11/26/2009 | WO2009140972A2 Modulation of the vps10p-domain receptors for the treatment of cardiovascular disease |
| 11/26/2009 | WO2009114098A3 Methods of treating hyperacidic disorders |
| 11/26/2009 | WO2009101199A3 Treatment of acne vulgaris; rosacea and rhinophym |
| 11/26/2009 | WO2009050506A3 Combination 059 |
| 11/26/2009 | WO2008145281A8 Formulations containing triazinones and iron |
| 11/26/2009 | US20090292113 Recombinant soluble Fc receptors |
| 11/26/2009 | US20090292112 provide polypeptides inter alia that have been identified as novel proteins with homology to the Mindin family of extracellular matrix proteins (RG1); prostate cancer or benign prostatic hyperplasia, which is alleviated by decreasing the level of RG1 activity |
| 11/26/2009 | US20090292016 Stable Pharmaceutical Compositions Containing Pravastatin |
| 11/26/2009 | US20090292000 Pyrrolidine derivatives as prostaglandin modulators |